Tomaralimab - Opsona Therapeutics

Drug Profile

Tomaralimab - Opsona Therapeutics

Alternative Names: Anti-TLR2 monoclonal antibody - Opsona Therapeutics; Anti-Toll-like receptor 2 monoclonal antibody - Opsona Therapeutics; OPN 305

Latest Information Update: 16 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opsona Therapeutics
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Toll like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Delayed graft function
  • Phase I/II Myelodysplastic syndromes
  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Feb 2018 Opsona Therapeutics initiates enrolment in a phase I/II follow up study of OPN-305-106 study for Myelodysplastic Syndrome (Second line therapy or greater) in Ireland (NCT03337451)
  • 16 Nov 2017 Opsona Therapeutics plans a phase I/II follow up study of OPN-305-106 study for Myelodysplastic Syndrome in Ireland (NCT03337451)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top